Publications by authors named "C Isca"
Several authors reported an increased risk of cancer in SSc patients, including breast cancer (BC). Nevertheless, the mechanisms underlying this association have not yet been clarified. SSc and BC share several molecular pathways, which seem to play a common etiopathogenetic role.
View Article and Find Full Text PDFBackground: Current guidelines consider T-DM1 the standard 2 line therapy for HER2 positive metastatic breast cancer (MBC) patients following trastuzumab (T) + pertuzumab (P) and taxane 1 line treatment. Despite this, there are no prospective studies supporting this sequence.
Methods: We performed a meta-analysis using real world data to determine the efficacy of T-DM1 after 1 line TP in HER2 positive MBC patients.
: Aims of the study were to explore outcomes and toxicities of chemotherapy-immunotherapy (CT-IT) for patients (pts) with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) in a real-world population. Clinical data of 26 pts with mNSCLC treated with CT-IT at our institution from January 2020 to January 2021 were collected retrospectively. Median follow-up time was 7.
View Article and Find Full Text PDFArticle Synopsis
- MicroRNAs (miRNAs) are tiny noncoding RNAs that can function as either oncogenes or tumor suppressors, and their improper expression is linked to various cancers, notably breast cancer.
- The study emphasizes the neoadjuvant setting as a prime model for understanding treatment resistance mechanisms in HER2-positive early breast cancer, especially with the advancements in targeted therapies.
- The review highlights key miRNAs associated with tumor growth in HER2-positive breast cancer and examines their potential as predictive and prognostic biomarkers for better treatment outcomes.